Integrated Biopharma INC Form 4 insider transactions
Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.
OQX
Eric J. Friedman, a Director at Integrated Biopharma Inc., has acquired 50,000 stock options with an exercise price of $0.19.
OQX
Damon DeSantis, Director and 10% Owner of Integrated Biopharma Inc., acquired 50,000 stock options on June 24, 2026.
OQX
Eric J. Friedman, a Director at Integrated Biopharma Inc., has acquired 50,000 stock options with an exercise price of $0.19.
OQX
Robert Canarick, a Director at Integrated Biopharma Inc., has acquired 50,000 stock options with an exercise price of $0.19.
OQX
William H. Milmoe, a Director at Integrated Biopharma Inc., has acquired 50,000 stock options with an exercise price of $0.19.
OQX
Director William H. Milmoe filed an amended Form 4 to correct the transaction date for the transfer of Integrated Biopharma, Inc. shares to CDDS 2.0, LLC.
OQX
Director William H. Milmoe reported the transfer of over 11 million shares of Integrated Biopharma common stock.
OQX
Carl DeSantis estate transfers over 11 million shares of Integrated BioPharma to an entity controlled by Damon DeSantis.
OQX
Director Damon DeSantis consolidated 11,201,964 shares of Integrated BioPharma, Inc. into CDDS 2.0, LLC.
OQX
A Form 4 filing reveals the posthumous transfer of over 1.3 million Integrated BioPharma shares by Carl DeSantis's estate to an entity controlled by Damon DeSantis.
OQX
William H. Milmoe, a Director and 10% owner of Integrated Biopharma Inc., reported transfers of common stock between related entities.
OQX
Damon DeSantis, a Director and 10% owner of Integrated BioPharma Inc., transferred over 1.3 million common shares to an entity he controls.
OQX
Integrated Biopharma's Co-CEO Christina Kay acquired 140,000 stock options with a $0.35 exercise price, vesting over three years.
OQX
Integrated BioPharma Inc. Co-CEO Riva Sheppard received a grant of 140,000 stock options with an exercise price of $0.35, vesting over three years.
OQX
Integrated Biopharma's CFO, Dina Masi, received a grant of 140,000 stock options with a $0.31 exercise price, vesting over three years.
OQX
Integrated Biopharma Inc. Director Damon DeSantis was granted 50,000 stock options with an exercise price of $0.30, vesting in quarterly installments through June 2026.
OQX
William H. Milmoe, a Director and 10% Owner of Integrated Biopharma Inc. (INBP), was granted 50,000 stock options with a $0.33 exercise price, vesting in four equal installments through June 2026.
OQX
Integrated Biopharma Inc. Director Eric J. Friedman was granted 50,000 stock options with an exercise price of $0.30, vesting in four equal installments through June 2026.
OQX
Integrated Biopharma Inc. Director Robert Canarick was granted 50,000 stock options with an exercise price of $0.3, vesting in four equal installments through June 2026.
OQX
Integrated Biopharma Inc. Director and 10% owner William H. Milmoe acquired 50,000 shares of common stock through the exercise of stock options at $0.09 per share, increasing his direct beneficial ownership to 138,667 shares.
OQX
Riva Sheppard, Co-CEO of Integrated BioPharma, acquired 144,445 shares of common stock through the exercise of stock options at a price of $0.09 per share.
OQX
Christina Kay, Co-Chief Executive Officer and Director of Integrated BioPharma Inc., reports the acquisition of 144,445 shares of common stock through the exercise of stock options.
OQX
Dina Masi, CFO of Integrated BioPharma Inc., acquired 135,000 shares of common stock by exercising stock options at $0.09 per share.
OQX
Director Robert Canarick acquired 175,000 shares of Integrated BioPharma Inc. through the exercise of stock options at $0.09 per share.
OQX
Christina Kay, Co-Chief Executive Officer of Integrated BioPharma, was granted 125,000 stock options on December 4, 2024.
OQX
Integrated BioPharma's Co-Chief Executive Officer, Riva Sheppard, was granted 125,000 stock options on December 4, 2024.
OQX
Integrated BioPharma's Chief Financial Officer, Dina Masi, was granted stock options for 125,000 shares on December 4, 2024.
OQX
Integrated BioPharma's Co-Chief Executive Officer, Riva Sheppard, exercised stock options to acquire 55,555 common shares at $0.09 per share.
OQX
Christina Kay, Co-Chief Executive Officer of Integrated BioPharma Inc., exercised stock options to acquire 55,555 common shares at $0.09 per share.
OQX
Integrated BioPharma's Chief Financial Officer, Dina Masi, exercised stock options to acquire 65,000 shares of common stock at $0.09 per share.